181 related articles for article (PubMed ID: 33704175)
1. Evolution of Systemic Treatment Uptake and Survival in Advanced Non-Small Cell Lung Cancer.
Stock-Martineau S; Laurie K; McKinnon M; Zhang T; Wheatley-Price P
Curr Oncol; 2020 Dec; 28(1):60-68. PubMed ID: 33704175
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
[TBL] [Abstract][Full Text] [Related]
3. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
4. Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018.
Wolf A; Stratmann JA; Shaid S; Niklas N; Calleja A; Ubhi H; Munro R; Waldenberger D; Carroll R; Daumont MJ; Penrod JR; Lacoin L; Rohde G
BMC Pulm Med; 2023 Jan; 23(1):16. PubMed ID: 36639770
[TBL] [Abstract][Full Text] [Related]
5. Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.
Schwartzberg L; Korytowsky B; Penrod JR; Zhang Y; Le TK; Batenchuk C; Krug L
Clin Lung Cancer; 2019 Jul; 20(4):287-296.e4. PubMed ID: 31130450
[TBL] [Abstract][Full Text] [Related]
6. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
8. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
Liang H; Song X; Zhang Y; Zhang S; Li F; Fang J; Li J; Liang L; Nie L; Ma K; Zhang L; Wang X; Xu J; Wei Y; Wang J; Song Q; Tian G; Mu Y; Gu Y; Yang L; Sun P; Zhong W; Zhao J; Xu Y; Chen M; Wang M
Thorac Cancer; 2019 Jul; 10(7):1521-1532. PubMed ID: 31144459
[TBL] [Abstract][Full Text] [Related]
9. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
10. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
Chen YM
J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
[TBL] [Abstract][Full Text] [Related]
11. The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.
Perdrizet K; Leighl NB
Curr Treat Options Oncol; 2019 Feb; 20(3):21. PubMed ID: 30778772
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma.
Bylicki O; Guisier F; Monnet I; Doubre H; Gervais R; Janicot H; Perol M; Fournel P; Lamy R; Auliac JB; Chouaid C
Medicine (Baltimore); 2020 Jan; 99(3):e18726. PubMed ID: 32011450
[TBL] [Abstract][Full Text] [Related]
13. Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study.
de Castro J; Tagliaferri P; de Lima VCC; Ng S; Thomas M; Arunachalam A; Cao X; Kothari S; Burke T; Myeong H; Grattan A; Lee DH
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28748556
[TBL] [Abstract][Full Text] [Related]
14. Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.
Sluga R; VAN DEN Borne BEEM; Roepman P; Peters BJM; Kastelijn EA; Schramel FMNH
Anticancer Res; 2018 Jan; 38(1):393-400. PubMed ID: 29277800
[TBL] [Abstract][Full Text] [Related]
15. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
17. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
19. Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis.
Aguilar KM; Winfree KB; Muehlenbein CE; Zhu YE; Wilson T; Wetmore S; Nadler ES
Adv Ther; 2018 Nov; 35(11):1905-1919. PubMed ID: 30341504
[TBL] [Abstract][Full Text] [Related]
20. Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.
Okamoto I; Morita S; Tashiro N; Imamura F; Inoue A; Seto T; Yamamoto N; Ohe Y; Nakagawa K; Fukuoka M
Lung Cancer; 2018 Mar; 117():14-19. PubMed ID: 29496250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
